Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Next Previous
Trial Profile

A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesevatinib (Primary) ; Trastuzumab
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions
  • Sponsors Kadmon Corporation

Most Recent Events

  • 28 Feb 2022 The primary endpoint has been changed from Safety: Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability and MTD to Safety and Tolerability: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) by Severity and/or Relationship to Tesevatinib and Safety and Tolerability: Percentage of Subjects With Serious Adverse Event (SAE) Related to Tesevatinib, according to ClinicalTrials.gov record.
  • 28 Aug 2017 Status changed from active, no longer recruiting to discontinued.
  • 29 Nov 2016 Planned primary completion date changed from 30 Sep 2016 to 1 Dec 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top